Pathogens (Sep 2023)

Comparison of CD4+/CD8+ Lymphocytic Subpopulations Pre- and Post-Antituberculosis Treatment in Patients with Diabetes and Tuberculosis

  • Erick J. Rendón Ramírez,
  • Adrián G. Rosas-Taraco,
  • Berenice Soto-Monciváis,
  • Perla R. Colunga-Pedraza,
  • Rosario Salazar-Riojas,
  • Nereida Méndez-Ramírez,
  • Alma Yolanda Arce-Mendoza,
  • Antonio Muñiz-Buenrostro,
  • Jorge Llaca-Díaz,
  • David Gomez-Almaguer,
  • Adrián Rendón

DOI
https://doi.org/10.3390/pathogens12091181
Journal volume & issue
Vol. 12, no. 9
p. 1181

Abstract

Read online

Is there a CD4+ and CD8+ immunity alteration in patients with pulmonary tuberculosis (TB) and diabetes (DM) that does not recover after antituberculosis treatment? This prospective comparative study evaluated CD4+ and CD8+ lymphocytic subpopulations and antituberculosis antibodies in patients with diabetes and tuberculosis (TB-DM), before and after antituberculosis treatment. CD4+ T cell counts were lower in patients with TB-DM compared to those with only TB or only DM, and these levels remained low even after two months of anti-TB treatment. Regarding the CD8+ T cell analysis, we identified higher blood values in the DM-only group, which may be explained by the high prevalence of latent tuberculosis (LTBI) in patients with DM. IgM antituberculosis antibodies levels were elevated in patients with only TB at baseline, and 2 months post-anti-TB treatment, IgG did not express any relevant alterations. Our results suggest an alteration in CD4+ immunity in patients with TB-DM that did not normalize after antituberculosis treatment.

Keywords